Score Overview
Explore the 2021 public Archive ranking →
Where Iradimed Co has ranked, year by year
Showing 5 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- IRMD
2020: 27.1% · 2021: 81.3% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-30 | $ 86.22 | — |
1 Year2025-09-30 | $ 70.19 | 22.84% |
5 Years2021-09-30 | $ 30.50 | 182.64% |
10 Years2016-09-30 | $ 15.43 | 458.80% |
All Time2014-07-16 | $ 8.99 | 9x |
| Period | Last Price2026-09-30 | 1 Year2025-09-30 | 5 Years2021-09-30 | 10 Years2016-09-30 | All Time2014-07-16 |
|---|---|---|---|---|---|
| Price | $ 86.22 | $ 70.19 | $ 30.50 | $ 15.43 | $ 8.99 |
| Return | — | 22.84% | 182.64% | 458.80% | 9x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 86M | $ 23M | $ 59M |
| 2025 | $ 83M | $ 22M | $ 51M |
| 2024 | $ 73M | $ 19M | $ 52M |
| 2023 | $ 65M | $ 17M | $ 49M |
| 2022 | $ 53M | $ 12M | $ 57M |
| 2021 | $ 41M | $ 9M | $ 62M |
| 2020 | $ 31M | $ 1M | $ 51M |
| 2019 | $ 38M | $ 9M | $ 46M |
| 2018 | $ 30M | $ 6M | $ 34M |
| 2017 | $ 23M | $ 499.76K | $ 26M |
| 2016 | $ 32M | $ 7M | $ 25M |
| 2015 | $ 31M | $ 7M | $ 26M |
| IPO2014 | $ 15M | $ 2M | $ 17M |
Iradimed Co fundamental performance
Between 2020 and 2025, revenue grew from $ 31M to $ 83M and net income grew from $ 1M to $ 22M. Revenue increased in every one of those 5 years; net income in every one.
Between 2015 and 2025, revenue grew from $ 31M to $ 83M and net income grew from $ 7M to $ 22M. Revenue increased in 8 of those 10 years; net income in 8.
Iradimed Co currently holds a 5-year HDB Score of 8.7 out of 10. How the HDB Score is calculated.
Membership
Continue IRMD’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
